Search Results - "Mosescu, Simona Elena"
-
1
Impact of CFTR Modulator Therapies on Liver Function in Cystic Fibrosis Patients: A Systematic Review of Hepatic Biomarkers
Published in Journal of gastrointestinal and liver diseases : JGLD (10-09-2024)“…Background and Aims: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, including elexacaftor/ivacaftor/tezacaftor (ETI) and…”
Get full text
Journal Article -
2
SWEAT CONDUCTIVITY IN THE DIAGNOSIS OF CYSTIC FIBROSIS – THE EXPERIENCE OF THE REGIONAL CENTRE “GRIGORE ALEXANDRESCU” EMERGENCY CHILDREN’S HOSPITAL
Published in Revista română de pediatrie (30-06-2017)“…Introduction. The sweat test is the standard method for the diagnosis of cystic fibrosis (CF). The sweat conductivity represents an alternative not yet…”
Get full text
Journal Article -
3
Genetic and clinical factors influencing CF-associated liver disease: the impact of SERPINA1 variants and CFTR genotypes in Romanian pediatric cystic fibrosis patients
Published in Medicine and pharmacy reports (01-10-2024)“…Background. Hepatic disease represents a significant complication in children with cystic fibrosis (CF), yet its relationship with specific genetic factors,…”
Get full text
Journal Article -
4
DETERMINAREA CONDUCTIVITĂŢII SUDORII ÎN DIAGNOSTICUL FIBROZEI CHISTICE – EXPERIENŢA CENTRULUI REGIONAL SCUC „GRIGORE ALEXANDRESCU
Published in Revista română de pediatrie (30-06-2017)Get full text
Journal Article -
5
DETERMINAREA CONDUCTIVITĂŢII SUDORII ÎN DIAGNOSTICUL FIBROZEI CHISTICE – EXPERIENŢA CENTRULUI REGIONAL SCUC „GRIGORE ALEXANDRESCU
Published in Revista română de pediatrie (01-06-2017)“…Introducere. Testul sudorii este metoda standard pentru diagnosticul fibrozei chistice (FC). Metoda conductivităţii reprezintă o alternativă ce nu este încă…”
Get full text
Journal Article -
6
Impact of CFTR modulatory therapies on liver function and fibrosis indices in cystic fibrosis patients: a retrospective analysis from two Romanian medical centers
Published in Medicine and pharmacy reports (24-10-2024)“…Background. Patients with cystic fibrosis (CF) frequently require modulatory therapies such as Lumacaftor/Ivacaftor (LI) and Elexacaftor/Tezacaftor/Ivacaftor…”
Get full text
Journal Article